Wendy La, PharmD

Implementing PrEP in retail community pharmacies increases patient accessibility but may be difficult to incorporate without modifying workflow.

Isatuximab and daratumumab offer promising treatment options for previously treated multiple myeloma.

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for previously treated HER2-positive breast cancer and gastric or gastroesophageal junction adenocarcinoma.

Ciprodex is approved for the treatment of ear infections, acute otitis media, and acute otitis externa.